Dr Nathan (Mount Vernon Cancer Centre, Northwood, UK) chaired a GSK sponsored promotional meeting at ASCO 2014 with Prof Schadendorf (Universitätsklinikum Essen, Essen, Germany) and Prof Long (University of Sydney, Sydney, Australia) about making patient focused treatment decisions in metastatic melanoma.
The session focussed on a discussion of dabrafenib monotherapy, a BRAF inhibitor for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation, in the context of a metastatic melanoma patient case study. An international expert panel shared their opinions on three key questions relating to patient management:
How can clinicians make patient-centred therapy choices in practice?
Once prescribed, how can dabrafenib therapy be optimised?
How should patients who respond to therapy be managed?
Paul Nathan, Dirk Schadendorf and Georgina Long
Filmed at the 50th ASCO Annual Meeting in Chicago, IL, USA
Not intended for US Healthcare Professionals
Material dirigido exclusivamente a profesionales sanitarios
Zinc code: OF/DBF/0011/14f Date of preparation: September 2014